|
WO2019168866A1
|
|
Substituted cyclohexyl compounds as nop inhibitors
|
|
AU2018373258A1
|
|
Substituted furanopyrimidine compounds as PDE1 inhibitors
|
|
US2019177327A1
|
|
Substituted methyl pyrazolopyrimidinone and methyl imidazopyrazinone compounds as pde1 inhibitors
|
|
CN111094293A
|
|
Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
|
|
US2020148685A1
|
|
Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
|
|
CA3034885A1
|
|
Hydroxynorketamine derivatives for the treatment of cns disorders
|
|
US2018057470A1
|
|
Compounds for therapeutic use
|
|
WO2016179434A1
|
|
Systems and methods for cognitive testing
|
|
CN106459062A
|
|
Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as PDE2 inhibitors
|
|
US2015050626A1
|
|
Systems, Methods, and Software for Improving Cognitive and Motor Abilities
|
|
WO2014158916A1
|
|
Substituted naphthyridine and quinoline compounds as mao inhibitors
|
|
CA2730940A1
|
|
Methods and systems for evaluating memory agents
|
